Mankind Pharma Ltd Total Assets
Mankind Pharma Ltd total assets. Based on the latest financial reports, Mankind Pharma Ltd (MANKIND) holds total assets worth Rs280.80 Billion INR (≈ $3.04 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MANKIND market cap for the company's overall valuation and market capitalisation.
Total Assets of Mankind Pharma Ltd (2019–2026)
Total assets of Mankind Pharma Ltd from 2019 to 2026. This chart illustrates how Mankind Pharma Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of Mankind Pharma Ltd for real-time trading data and today's change.
Mankind Pharma Ltd - Asset Composition Analysis
Mankind Pharma Ltd Total Assets Breakdown (March 2026)
Mankind Pharma Ltd total assets breakdown as of March 2026. Mankind Pharma Ltd's total assets of Rs280.80 Billion consist of 24.8% current assets and 75.2% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.7% |
| Accounts Receivable | Rs17.34 Billion | 6.2% |
| Inventory | Rs21.44 Billion | 7.6% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs96.41 Billion | 34.3% |
| Goodwill | Rs64.93 Billion | 23.1% |
Asset Composition Trend (2019–2026)
This chart illustrates how Mankind Pharma Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Mankind Pharma Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mankind Pharma Ltd's current assets represent 24.8% of total assets in 2026, a decrease from 48.6% in 2019.
- Cash Position: Cash and equivalents constituted 1.7% of total assets in 2026, down from 2.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 57.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 34.3% of total assets.
Mankind Pharma Ltd Competitors by Total Assets
Key competitors of Mankind Pharma Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Mankind Pharma Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.07 | 1.23 | 1.68 |
| Quick Ratio | 0.74 | 0.86 | 1.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs4.47 Billion | Rs13.25 Billion | Rs17.83 Billion |
Mankind Pharma Ltd - Advanced Valuation Insights
This section examines the relationship between Mankind Pharma Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.74 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 1.2% |
| Total Assets | Rs280.80 Billion |
| Market Capitalization | $11.14 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Mankind Pharma Ltd's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Mankind Pharma Ltd's assets grew by 1.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Mankind Pharma Ltd (2019–2026)
The table below shows the annual total assets of Mankind Pharma Ltd from 2019 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs280.80 Billion ≈ $3.04 Billion |
+1.15% |
| 2025-03-31 | Rs277.60 Billion ≈ $3.00 Billion |
+132.04% |
| 2024-03-31 | Rs119.63 Billion ≈ $1.29 Billion |
+23.14% |
| 2023-03-31 | Rs97.15 Billion ≈ $1.05 Billion |
+6.21% |
| 2022-03-31 | Rs91.48 Billion ≈ $989.29 Million |
+43.55% |
| 2021-03-31 | Rs63.73 Billion ≈ $689.18 Million |
+25.61% |
| 2020-03-31 | Rs50.73 Billion ≈ $548.66 Million |
+23.36% |
| 2019-03-31 | Rs41.12 Billion ≈ $444.74 Million |
-- |
About Mankind Pharma Ltd
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, resp… Read more